MU COULTER BIOMEDICAL
ACCELERATOR
MIDWEST BIOMEDICAL
ACCELERATOR CONSORTIUM
“Translating academic biomedical innovations into products that
improve patient care and public health”
$1M+/year in funding, project management
and commercialization support for
MU innovators
$1M+/year in funding, project management
and commercialization support for
UM System and KU innovators
Jaya Ghosh, PhD
MU Coulter Program Director
MBArC Lead Program Manager
Phone: (573) 882-0522
Email: ghoshj@missouri.edu
What is the problem?
ARTHROFIBROSIS
Loss of Motion
Pain and Disability
Diminished Quality of Life
$$$$$
How does BioJoint Flex solve the problem?
• An affordable, easy to
use knee range of
motion device that
provides a gentle,
prolonged stretch for
people experiencing
motion loss
ARTHROFIBROSIS
What is the market use?
25% of US adults have knee
pain (60.5 million people)
>1 million major knee
surgeries/year
>75,000
patients per
year with
arthrofibrosis
following
surgery
Patient version
HCPCS code E1811 –
Medicare reimburses $149
Pro version
Market price ~$500
10% Entry Market Share over first 3-5 years
7,500 patient units
+
1,000 pro units
=
$1.1M/yr
What competition exists?
FEATURES: JAS Brace CPM Physical Therapy Surgery
Early Intervention X X X
Gentle X
Affordable ~$700 $100/wk $75-150/session $6,000-10,000
Clinic Use X X X
Home Use X X
Prolonged Stretch X
Track Record X X X
ARTHROFIBROSIS
Loss of Motion
Pain and Disability
Diminished Quality of Life
✓
✓
$149*
✓
✓
✓
✗
What is the status of the intellectual property?
• US nonprovisional patent application pending
– Application No. 16/180,783
– Publication No. US 2019/0133864
– “Knee Flexion Device and Associated Method of Use”
– Filing Date: November 5, 2018
• Evaluation revealed other devices that promote knee
mobility, but nothing with similar specifications
Patent/ Application # Patent/Application Title Status
Application: 16/180,783 Knee Flexion Device and
Associated Method of Use
Pending
What is the stage of development?
• Prototypes developed
and tested in initial
prospective randomized
clinical trial
• Complete data for 29
patients
– BioJoint Flex = 16
• 6F, 10M mean age 63 yrs
– Control = 13
• 10F, 3M mean age 64 yrs
Does it work?
• BETTER Flexion
• BETTER Function*
• BETTER Pain Relief*
• BETTER Patient Satisfaction
• Safe, Comfortable, Easy to Use
0
20
40
60
80
100
120
140
PreOP 6w 12w
BJF Standard PT
Knee Flexion
measured with goniometer
0
10
20
30
40
50
60
70
80
90
100
PreOP 6w 12w
BJF Standard PT
Knee Function
based on IKDC PROM
* = statistically significant difference (p<0.05)
Knee Pain
based on VAS PROM
0
1
2
3
4
5
6
7
8
9
10
PreOP 6w 12w
BJF Standard PT
0
1
2
3
4
5
6
7
8
9
10
BJF Standard PT
Patient Satisfaction
$$$$$$$$$$
What is needed for further development?
• Experienced Licensee with expertise in
orthopaedic device manufacturing,
sales and distribution
– Invest ~$1M for manufacturing, assembly,
and marketing of product for year 1
• Finalize Patient version
– $50 → $149
• Finalize Pro version
– Features: motorized, sensors,
microcontroller, digital display, blue tooth,
multi-use
– $100 → $500
• Regulatory Pathway
– 510K Exempt – Class 1 = safe & effective
• READY for commercialization
Jimi Cook, DVM, PhD, OTSC
Clinical Research & Development
Trent Guess, PhD
Engineering & Manufacturing
Cory Crecelius, PT
Clinical Implementation
Kylee Rucinski, MHA
Healthcare Financials
Sam Bish, PhD
Technology Advancement
The Mizzou BioJoint Flex Team